Millennium Management LLC trimmed its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 33.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 801,971 shares of the biotechnology company’s stock after selling 410,297 shares during the quarter. Millennium Management LLC’s holdings in Sarepta Therapeutics were worth $44,622,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. BlackRock Inc. increased its stake in Sarepta Therapeutics by 0.9% in the fourth quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock valued at $349,773,000 after acquiring an additional 58,433 shares during the last quarter. Fred Alger Management Inc. grew its stake in shares of Sarepta Therapeutics by 10.5% during the fourth quarter. Fred Alger Management Inc. now owns 1,581,525 shares of the biotechnology company’s stock worth $87,996,000 after buying an additional 149,712 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock worth $63,998,000 after buying an additional 6,357 shares during the last quarter. Eagle Asset Management Inc. grew its stake in shares of Sarepta Therapeutics by 26.0% during the third quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock worth $49,858,000 after buying an additional 207,810 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC grew its stake in shares of Sarepta Therapeutics by 63.4% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 872,824 shares of the biotechnology company’s stock worth $48,564,000 after buying an additional 338,737 shares during the last quarter. 84.93% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

A number of research firms have weighed in on SRPT. Morgan Stanley cut shares of Sarepta Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $64.00 to $87.00 in a research note on Wednesday. SunTrust Banks boosted their target price on shares of Sarepta Therapeutics to $95.00 and gave the stock a “buy” rating in a research note on Friday, March 16th. BidaskClub raised shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 15th. Royal Bank of Canada reaffirmed a “buy” rating and set a $91.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, March 14th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Sarepta Therapeutics from $75.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $76.40.

Sarepta Therapeutics stock opened at $79.91 on Thursday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 12.96 and a current ratio of 13.91. Sarepta Therapeutics Inc has a fifty-two week low of $28.14 and a fifty-two week high of $84.37.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). The business had revenue of $57.30 million for the quarter, compared to analyst estimates of $57.33 million. Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. Sarepta Therapeutics’s revenue for the quarter was up 961.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.71) EPS. equities research analysts forecast that Sarepta Therapeutics Inc will post -1.18 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/sarepta-therapeutics-inc-srpt-position-cut-by-millennium-management-llc/1957355.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.